Brought to you by:
Bryan Kay
Novel sirolimus-eluting scaffold system demonstrates ‘potential to address Achilles’ heel’ of currently available endovascular treatment options
Ongoing studies of the Efemoral vascular scaffold system (EVSS)—previously described as a potential new paradigm in the treatment of long occlusive lesions—show that the device continues to show promise, according to investigators. The latest animal study assessed the subacute response…
How physician assistants help vascular surgery teams provide ‘continuity of care’
The key role played by physician assistants (PAs) as part of vascular surgery teams in the U.S. came into focus during the Vascular Societies’ Annual Scientific Meeting in Brighton, England. Julie Ann Freischlag, MD, the former Society for Vascular Surgery…
Vascular trainees better prepared for open aortic practice than commonly reported, new study shows
Current graduates from both vascular surgery residency and fellowship programs are well prepared for surgical practice in aortic disease whether they are performing open repair or endovascular therapy, contrasting with research indicating that trainees are entering the workforce with inadequate…
The endovascular revolution and open aortic training: ‘It’s not necessarily a crisis but it could become one’
Jean Panneton, MD, considers himself what he terms a “blue-collar” vascular surgeon as much as one engaged in academic practice and the necessity of helping contribute to the next generation of vascular surgeons. He operates. And he operates a lot.…
Merit Medical announces FDA approval of the Wrapsody cell-impermeable endoprosthesis
Merit Medical Systems announced today that the Wrapsody cell-impermeable endoprosthesis has received premarket approval from the US Food and Drug Administration (FDA). With this approval, a press release notes, Merit can begin commercialisation of the device in the USA in…
Positive one-year data for new venous valve portends promising future in chronic venous insufficiency treatment
SAVVE trial principal investigators discuss results showing 98.4% VenoValve device patency, 85% clinically meaningful benefit and an 80% rate of ulcer size reduction at 12 months. Fresh from delivering positive one-year data from the Surgical Antireflux Venous Valve Endoprosthesis (SAVVE)…
Novel bioabsorbable perivascular wrap aims to reduce AVF failure
Ellen Dillavou, MD, division chief of vascular surgery at WakeMed Heart Center in Raleigh, North Carolina, primary investigator (PI) for the VenoStent trial, presented new data during the 2024 VEITHsymposium in New York City (Nov. 19–23) about the SelfWrap (VenoStent)…
When RCTs are essential for novel vascular access device regulation
As part of a 2024 VEITHsymposium (New York City; Nov. 19–23) debate, Robert E Lee, MD, a medical officer recently retired from the Food and Drug Administration (FDA), presented an argument in favor of when the use of randomized controlled…
Artivion granted FDA humanitarian device exemption for the AMDS hybrid prosthesis
Artivion recently announced that the Food and Drug Administration (FDA) has granted a humanitarian device exemption (HDE) for use of the AMDS hybrid prosthesis (formerly known as the Ascyrus Medical dissection stent) in acute DeBakey type I dissections in the…
VASC.AI: Canadian vascular surgery researchers develop vascular-specific bot aimed at aiding education and clinical practice
The advent of large language models such as ChatGPT (Open AI) has left little of the world untouched—and a quintet of University of Toronto vascular surgery researchers are bidding to harness this mode of artificial intelligence (AI) and refine it…